ALISO VIEJO, Calif., May 6, 2008 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced the appointment of John T. Buhler as Vice President of International Sales and Business Development. Most recently, Buhler served as President and Chief Executive Officer of Ultrasonix Medical Corporation, a privately held company based in Richmond, British Columbia, focused on development and manufacturing of high-quality diagnostic ultrasound imaging systems. Ultrasonix was recognized as the 2007 Medical Device Company of the Year by LifeSciences British Columbia.
"We are pleased to have John join SenoRx's senior management team," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "In his new role, John will direct our efforts to globalize our business and develop strong relationships with the leading imaging companies, including collaboration in product development and marketing. He will also direct international distributor sales, business development, customer service and corporate management information systems.
"John's proven track record of building growth-oriented organizations in both large and small companies will further strengthen our management team and help us capitalize on significant opportunities to globalize our business, align with imaging companies and benefit from operating efficiencies. John's skills will be an excellent complement to Bill Gearhart, who as Vice President of Sales and Marketing, focuses primarily on our direct selling channel. In his role at Ultrasonix, John grew a $1 million company into a $30 million multinational enterprise in less than three years, and successfully directed the Ultrasonix ultrasound system market entry into 65 countries," added Malchow.
Prior to his position at Ultrasonix, John worked for General Electric for seven years, where he last served as Vice President and General Manager of Ultrasound Performance Technologies directing a global division focused on high-growth ultrasound markets and compact technologies. Earlier with GE, he led GE's commercial Ultrasound operations throughout Asia delivering double-digit margin growth annually while based out of Shanghai, China. Prior to joining General Electric, John spent 16 years with Diasonics, Inc., advancing to the role of Vice President of Operations at Diasonics Inc., which was purchased by General Electric in 1998.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx has recently launched several of its products through distributors in more than 15 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning globalizing our business, developing relationships with imaging companies and achieving operating efficiencies are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its most recent annual report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.